

# PROVIDER BULLETIN

## PROVIDER INFORMATION



December 1, 2023

### Medical Policy Updates: Coupe Health and Self-Funded Benefit Plans managed by Blue Cross and Blue Shield of Alabama

Participating providers are invited to submit for consideration scientific, evidence-based information, professional consensus opinions, and other information supported by medical literature relevant to our draft policies for Coupe Health and Self-Funded benefit plans managed by Blue Cross and Blue Shield of Alabama.

The draft policies are available for physician comment for 45 days from the posting date found on the document. At the conclusion of the 45 days, policies will go into effect. Make sure your voice is heard by providing feedback directly to us.

#### How to Submit Comments on Draft Medical Policies

[Complete our medical policy feedback form](https://mn-policies.exploremyplan.com/portal/web/mn-policies/feedback) online at <https://mn-policies.exploremyplan.com/portal/web/mn-policies/feedback> or send comments and supporting documentation to us by mail or fax:

Birmingham Service Center  
Attn: Health Management - Medical Policy  
P.O. Box 10527  
Birmingham, AL 35202  
Fax: 205-220-0878

#### Draft Medical Policies

Draft medical policies can be found at [Policies & Guidelines \(exploremyplan.com\)](https://mn-policies.exploremyplan.com/portal/web/mn-policies/feedback)

Policy #	Policy Title
MP-038	Continuous Glucose Monitoring Systems
MP-537	Peroral Endoscopic Myotomy (POEM) for Treatment of Esophageal Achalasia and Refractory Gastroparesis
MP-548	Identification of Microorganisms Using Nucleic Acid Probes
MP-748	Remote Electrical Neuromodulation for Migraines
MP-754	Annular Closing Device

#### Draft Provider-Administered Drug Policies

Draft provider-administered drug policies can be found at [Policies & Guidelines \(exploremyplan.com\)](https://mn-policies.exploremyplan.com/portal/web/mn-policies/feedback) and [Policies & Guidelines \(exploremyplan.com\)](https://mn-policies.exploremyplan.com/portal/web/mn-policies/feedback)

<b>Policy #</b>	<b>Policy Title</b>
PH-90002	Actemra IV
PH-90670	Amvuttra (vutrisiran)
PH-90497	Beovu (brolucizumab-dblI)
PH-90018	Berinert (C1 Esterase inhibitor, Human)
PH-90693	Briumvi (ublituximab-xiiy)
PH-90028	Cimzia (certolizumab pegol)
PH-90273	Cinqair (reslizumab)
PH-90168	Cinryze C1 Esterase inhibitor, Human)
PH-90098	Denosumab
PH-90660	Enjaymo (sutimlimab-jome)
PH-90202	Entyvio (vedolizumab)
PH-90347	Fasenra (benralizumab)
PH-90061	Hyaluronic Acid Derivatives
PH-90177	Ilaris (canakinumab)
PH-90104	Infliximab
PH-90167	Kalbitor (ecallantide)
PH-90158	Krystexxa (pegloticase)
PH-90223	Lemtrada (alemtuzumab)
PH-90133	Natalizumab
PH-90260	Nucala (mepolizumab)
PH-90298	Ocrevus (ocrelizumab)
PH-90379	Onpattro (patisiran lipid complex)
PH-90078	Ranibizumab
PH-90503	Reblozyl (luspatercept-aamt)
PH-90207	Ruconest (C1 Esterase inhibitor, recombinant)
PH-90176	Simponi_ARIA (golimumab)
PH-90674	Spevigo (spesolimab)
PH-90117	Stelara (ustekinumab)
PH-90634	Susvimo (ranibizumab)
PH-90697	Syfovre (pegcetacoplan)
PH-90549	Uplizna (inebilizumab-cdon)
PH-90659	Vabysmo (faricimab-svoa)
PH-90146	Xolair (omalizumab)
PH-9400	Botulinum Toxin
PH-9402	Eptinezumab (Vyepiti)
PH-9403	Immunoglobulin Therapy
PH-9406	Rituximab